FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088389318> ?p ?o ?g. }

• W3088389318 endingPage "S881" @default.
• W3088389318 startingPage "S881" @default.
• W3088389318 abstract "The prognosis of non-small-cell lung cancer (NSCLC) patients with driver gene wild type or positive and drug resistance combined with multiple brain metastases is still poor. Radiotherapy combined with anti-angiogenesis drugs may be a promising treatment option. Anlotinib had significantly improved progression-free survival (PFS) and overall survival (OS) of advanced NSCLC in ALTER0303 trial. This study aimed to evaluate the efficacy and safety of anlotinib combined with WBRT in patients with brain metastases (>3) from advanced NSCLC. Advanced NSCLC patients with brain metastases (>3) who were histologically confirmed to be driver gene wild type or positive (resistance after standard therapy) were treated with anlotinib (12 mg, QD, day 1 to 14 of a 21-day cycle) combined with WBRT (DT 30Gy/12 times) until disease progression or treatment intolerance. The primary endpoint was intracranial progression-free survival (iPFS). OS, PFS and toxicity were secondary endpoints. At data cut-off (April 30, 2020), we recruited 20 patients in this trial, of which 10 patients were evaluable. Among the 10 patients, 6 patients experienced partial response (PR) and 3 patients had stable disease (SD) in intracranial evaluation, and PR was achieved by 1 patient and SD exhibited by 8 patients in extracranial evaluation. The median iPFS was not reached and the six-month iPFS rate was 87.5% (95%CI, 67.3%-100%). The median extracranial PFS was 8.7 months (95%CI, 3.52-13.87). The objective response rate (ORR) and the disease control rate (DCR) were 60.0% and 90.0% in intracranial evaluation, respectively. The extracranial ORR was 10.0%, and DCR was 90.0%. Most common grade 1-2 adverse events (AEs) were hypertension (60%), fatigue (50%) and anorexia (40%). 2 patients (20%) suffered from grade 3 AEs, which were hypertension and hand-foot syndrome, respectively. No intracranial hemorrhage occurred during treatment. The combination of anlotinib and WBRT exhibited significantly therapeutic efficacy and manageable AEs, which might be a promising option for patients with advanced NSCLC with multiple brain metastases." @default.
• W3088389318 created "2020-10-01" @default.
• W3088389318 creator A5005431305 @default.
• W3088389318 creator A5005724266 @default.
• W3088389318 creator A5007600334 @default.
• W3088389318 creator A5035948175 @default.
• W3088389318 creator A5037109362 @default.
• W3088389318 creator A5050895396 @default.
• W3088389318 creator A5064604780 @default.
• W3088389318 creator A5064748213 @default.
• W3088389318 creator A5066517120 @default.
• W3088389318 creator A5087168495 @default.
• W3088389318 date "2020-09-01" @default.
• W3088389318 modified "2023-09-27" @default.
• W3088389318 title "1386P Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases: An open-label, single-arm phase II trial" @default.
• W3088389318 doi "https://doi.org/10.1016/j.annonc.2020.08.1700" @default.
• W3088389318 hasPublicationYear "2020" @default.
• W3088389318 type Work @default.
• W3088389318 sameAs 3088389318 @default.
• W3088389318 citedByCount "1" @default.
• W3088389318 countsByYear W30883893182022 @default.
• W3088389318 crossrefType "journal-article" @default.
• W3088389318 hasAuthorship W3088389318A5005431305 @default.
• W3088389318 hasAuthorship W3088389318A5005724266 @default.
• W3088389318 hasAuthorship W3088389318A5007600334 @default.
• W3088389318 hasAuthorship W3088389318A5035948175 @default.
• W3088389318 hasAuthorship W3088389318A5037109362 @default.
• W3088389318 hasAuthorship W3088389318A5050895396 @default.
• W3088389318 hasAuthorship W3088389318A5064604780 @default.
• W3088389318 hasAuthorship W3088389318A5064748213 @default.
• W3088389318 hasAuthorship W3088389318A5066517120 @default.
• W3088389318 hasAuthorship W3088389318A5087168495 @default.
• W3088389318 hasBestOaLocation W30883893181 @default.
• W3088389318 hasConcept C126322002 @default.
• W3088389318 hasConcept C141071460 @default.
• W3088389318 hasConcept C143998085 @default.
• W3088389318 hasConcept C203092338 @default.
• W3088389318 hasConcept C2776256026 @default.
• W3088389318 hasConcept C2776694085 @default.
• W3088389318 hasConcept C2778822529 @default.
• W3088389318 hasConcept C2780739268 @default.
• W3088389318 hasConcept C31760486 @default.
• W3088389318 hasConcept C509974204 @default.
• W3088389318 hasConcept C535046627 @default.
• W3088389318 hasConcept C71924100 @default.
• W3088389318 hasConceptScore W3088389318C126322002 @default.
• W3088389318 hasConceptScore W3088389318C141071460 @default.
• W3088389318 hasConceptScore W3088389318C143998085 @default.
• W3088389318 hasConceptScore W3088389318C203092338 @default.
• W3088389318 hasConceptScore W3088389318C2776256026 @default.
• W3088389318 hasConceptScore W3088389318C2776694085 @default.
• W3088389318 hasConceptScore W3088389318C2778822529 @default.
• W3088389318 hasConceptScore W3088389318C2780739268 @default.
• W3088389318 hasConceptScore W3088389318C31760486 @default.
• W3088389318 hasConceptScore W3088389318C509974204 @default.
• W3088389318 hasConceptScore W3088389318C535046627 @default.
• W3088389318 hasConceptScore W3088389318C71924100 @default.
• W3088389318 hasLocation W30883893181 @default.
• W3088389318 hasOpenAccess W3088389318 @default.
• W3088389318 hasPrimaryLocation W30883893181 @default.
• W3088389318 hasRelatedWork W2133349049 @default.
• W3088389318 hasRelatedWork W2592092676 @default.
• W3088389318 hasRelatedWork W2789668336 @default.
• W3088389318 hasRelatedWork W2889701300 @default.
• W3088389318 hasRelatedWork W2902679640 @default.
• W3088389318 hasRelatedWork W3094659495 @default.
• W3088389318 hasRelatedWork W3171492215 @default.
• W3088389318 hasRelatedWork W4200446577 @default.
• W3088389318 hasRelatedWork W4229045579 @default.
• W3088389318 hasRelatedWork W4304690509 @default.
• W3088389318 hasVolume "31" @default.
• W3088389318 isParatext "false" @default.
• W3088389318 isRetracted "false" @default.
• W3088389318 magId "3088389318" @default.
• W3088389318 workType "article" @default.